Page 7 of 10 – SEC Filing Item 5. Interest in Securities of the Issuer. (a)-(c) As of the date hereof, Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler may be deemed to be the beneficial owner of 4,286,291 shares of Common Stock or 14.52% of the shares of the Common Stock of the Issuer, based upon the 29,514,448 shares of Common Stock outstanding as of August 3, 2016, according to the Form 10-Q filed by the Issuer on August 9, 2016. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler has the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 4,286,291 shares of Common Stock. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund and Kevin Kotler has the sole power to dispose or direct the disposition of 0 shares of Common Stock and the shared power to dispose or direct the disposition of 4,286,291 shares of Common Stock. Transactions in the Issuer in the last 60 Days is filed herewith as Exhibit B. The Reporting Persons specifically disclaim beneficial ownership in the shares of Common Stock reported herein except to the extent of their pecuniary interest therein.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Please see Item 4.
Item 7. Material to be Filed as Exhibits.
An agreement relating to the filing of a joint statement as required by Rule 13d-1(f) under the Securities Exchange Act of 1934 is filed herewith as Exhibit A. Transactions in the Issuer in the last 60 Days is filed herewith as Exhibit B. A copy of the Voting Agreement, filed by the Issuer on June 17, 2016 as Exhibit 10.5 of the Form 425, and incorporated herein by reference. For a complete description of the Merger Agreement see the Form 8-K filed by the Issuer on June 15, 2016 (which includes a copy of the Merger Agreement filed as exhibit 2.1 thereto). A copy of the Consent of Kevin Kotler to serve as director, filed by QLT on September 12, 2016 as Exhibit 99.10 of the Form S-4, and incorporated herein by reference.
| Item 5. | Interest in Securities of the Issuer. | |||
| (a)-(c) | As of the date hereof, Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler may be deemed to be the beneficial owner of 4,286,291 shares of Common Stock or 14.52% of the shares of the Common Stock of the Issuer, based upon the 29,514,448 shares of Common Stock outstanding as of August 3, 2016, according to the Form 10-Q filed by the Issuer on August 9, 2016. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler has the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 4,286,291 shares of Common Stock. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund and Kevin Kotler has the sole power to dispose or direct the disposition of 0 shares of Common Stock and the shared power to dispose or direct the disposition of 4,286,291 shares of Common Stock. Transactions in the Issuer in the last 60 Days is filed herewith as Exhibit B. The Reporting Persons specifically disclaim beneficial ownership in the shares of Common Stock reported herein except to the extent of their pecuniary interest therein. | |||
| Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect | ||
| to Securities of the Issuer. | |||
| Please see Item 4. | |||
| Item 7. | Material to be Filed as Exhibits. |
| An agreement relating to the filing of a joint statement as required by Rule 13d-1(f) under the Securities Exchange Act of 1934 is filed herewith as Exhibit A. Transactions in the Issuer in the last 60 Days is filed herewith as Exhibit B. A copy of the Voting Agreement, filed by the Issuer on June 17, 2016 as Exhibit 10.5 of the Form 425, and incorporated herein by reference. For a complete description of the Merger Agreement see the Form 8-K filed by the Issuer on June 15, 2016 (which includes a copy of the Merger Agreement filed as exhibit 2.1 thereto). A copy of the Consent of Kevin Kotler to serve as director, filed by QLT on September 12, 2016 as Exhibit 99.10 of the Form S-4, and incorporated herein by reference. | ||
Follow Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)
Follow Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
